Small Cell Lung Cancer

In this edition, single-fraction SBRT outcomes for central lung tumors, adjuvant durvalumab extends survival in limited-stage small cell lung cancer and more.

The FDA approved atezolizumab and hyaluronidase-tqjs for subcutaneous injection.

A randomized phase 3 trial designed to compare two combinations for first-line treatment of lung cancer has been halted after an interim analysis revealed no survival benefit and more toxicity with the experimental regimen.

In a study of patients with small cell lung cancer and idiopathic pulmonary fibrosis receiving carboplatin, etoposide and nintedanib, the primary endpoint was met, according to results published in Annals of the American Thoracic Society.

An analysis of the online conversations of more than 1,000 health care professionals worldwide through May revealed positive reactions to the approval of three key treatment options for patients with cancer.

CHICAGO — Durvalumab conferred significant survival benefits in patients with limited-stage small-cell lung cancer following standard-of-care treatment in a randomized phase 3 trial, according to findings presented at ASCO Annual Meeting.

The FDA granted accelerated approval to tarlatamab-dlle for treatment of certain patients with extensive-stage small cell lung cancer.

Durvalumab extended OS and PFS compared with placebo for patients with limited-stage small cell lung cancer, according to topline data released by the agent’s manufacturer.

The FDA granted fast track designation to PT217, a novel bispecific antibody, for the treatment of adults with extensive-stage small cell lung cancer, according to a release from the manufacturer.

Taofeek K. Owonikoko, MD, PhD, has been named executive director of University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.